154 related articles for article (PubMed ID: 30630683)
1. Fluorodeoxyglucose Detected Changes in Brain Metabolism After Chemotherapy in Pediatric Non-Hodgkin Lymphoma.
Shrot S; Abebe-Campino G; Toren A; Ben-Haim S; Hoffmann C; Davidson T
Pediatr Neurol; 2019 Mar; 92():37-42. PubMed ID: 30630683
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a cardiac metabolic switch in patients with Hodgkin's lymphoma.
Heckmann MB; Totakhel B; Finke D; Anker MS; Müller-Tidow C; Haberkorn U; Katus HA; Lehmann LH
ESC Heart Fail; 2019 Aug; 6(4):824-829. PubMed ID: 31278857
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effects of chemotherapy on brain glucose metabolism in children with Hodgkin's lymphoma.
Tauty A; Noblet V; Paillard C; Fornecker LM; Namer IJ; Bund C
Ann Nucl Med; 2019 Aug; 33(8):564-569. PubMed ID: 31087250
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging for Predicting Venous Thromboembolism in Children With Lymphoma.
Beall M; Deep K; Tram NK; Nabavinia M; Janse SA; Chou TH; Hardisky D; Bobbey AJ; Kerlin BA; Audino AN; Stacy MR
Circ Cardiovasc Imaging; 2023 Apr; 16(4):e014992. PubMed ID: 37013817
[TBL] [Abstract][Full Text] [Related]
7. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
[TBL] [Abstract][Full Text] [Related]
8. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
[TBL] [Abstract][Full Text] [Related]
9. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma.
Riad R; Omar W; Sidhom I; Zamzam M; Zaky I; Hafez M; Abdel-Dayem HM
Nucl Med Commun; 2010 Mar; 31(3):232-8. PubMed ID: 20032800
[TBL] [Abstract][Full Text] [Related]
10. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
11. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy.
Lavely WC; Delbeke D; Greer JP; Morgan DS; Byrne DW; Price RR; Hallahan DE
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):307-15. PubMed ID: 12957239
[TBL] [Abstract][Full Text] [Related]
12. Detection of unsuspected recurrent lymphoma with fluorodeoxyglucose-positron emission tomographic imaging after induction chemotherapy: a case study.
Alavi JB; Bénard F; Alavi A
Am J Clin Oncol; 1998 Apr; 21(2):126-8. PubMed ID: 9537195
[TBL] [Abstract][Full Text] [Related]
13. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
14. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
15. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
Bakhshi S; Radhakrishnan V; Sharma P; Kumar R; Thulkar S; Vishnubhatla S; Dhawan D; Malhotra A
Radiology; 2012 Mar; 262(3):956-68. PubMed ID: 22357895
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG-PET/CT Pulmonary Infiltrates in Non-Hodgkin Lymphoma Patients Treated with Combined Immunochemotherapy: Incidence and Clinical Characteristics.
Cohen YC; Berger T; Eshel L; Stern D; Bairey O; Raanani P; Shpilberg O
Isr Med Assoc J; 2017 Jun; 19(6):372-377. PubMed ID: 28647936
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children.
Wang SS; Mechinaud F; Thursky K; Cain T; Lau E; Haeusler GM
J Paediatr Child Health; 2018 May; 54(5):487-492. PubMed ID: 29235187
[TBL] [Abstract][Full Text] [Related]
19. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.
Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK
Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma.
Badr S; Kotb M; Elahmadawy MA; Moustafa H
Clin Nucl Med; 2018 Dec; 43(12):e428-e438. PubMed ID: 30358625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
